Neil Warma
Chief Executive Officer,
ProMIS Neurosciences
Canada
Neil became interim CEO of ProMIS Neurosciences in January 2024. Prior to that he was CEO of Genexine, where he led the company’s restructuring and commercialization of its first products. Previously, Neil was the US General Manager of I-Mab Biopharma U.S., where he responsible for the expansion of global operations and a key driver in I-Mab’s U.S. IPO.
Prior to that, Neil was President and CEO of Opexa Therapeutics, Inc. a biopharmaceutical company developing novel cellular therapies for autoimmune diseases. Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.
He spent several years in key management roles at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in Global Marketing and as Head of International Pharma Policy. He was also President and Co-Founder of MedExact, a health-technology company dedicated to providing an interface between physicians and pharmaceutical companies.
Suffix
Not Applicable
Sessions
-
10-Feb-2025ProMIS Neurosciences, Inc.
)
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}